Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Tenaya Therapeutics (NASDAQ:TNYA) granted stock options to new employees under its 2024 Inducement Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The company granted options to purchase 1,650,000 shares of common stock to newly appointed CFO Eric Hyllengren and an aggregate of 187,200 shares to two new non-executive employees.
The options have a ten-year term and an exercise price of $0.8365 per share, equal to the closing price on July 13, 2026. Vesting occurs over four years, with 25% vesting on the one-year anniversary of hire and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service.
Positive
- 1,650,000 stock options granted to new CFO as employment inducement
- Additional 187,200 options granted to two new non-executive employees
- Four-year vesting schedule with ten-year term supports longer-term employee retention
Negative
- New inducement options covering 1,837,200 shares may increase future share count
News Explained
The key structural point is that the July 14 disclosure concerns options to purchase common stock, not an immediate issuance of those shares; the release says vesting depends on continued service over four years.
News Market Reaction – TNYA
In the Jul 15 session, TNYA declined 2.48%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 29 | CFO appointment | Positive | +2.4% | Named experienced biotech finance executive Eric Hyllengren as new CFO. |
| Jun 03 | Clinical data update | Positive | -0.5% | Interim MyPEAK-1 TN-201 data showed cardiac remodeling and symptom reductions. |
| Jun 02 | Data presentation notice | Neutral | -0.5% | Scheduled release of new interim MyPEAK-1 TN-201 data and webcast details. |
| May 29 | Conference participation | Neutral | +8.8% | Announced participation and CEO presentation at Jefferies Global Healthcare Conference. |
| May 15 | Clinical data update | Positive | -8.3% | Positive interim RIDGE-1 TN-401 data with meaningful arrhythmia burden reductions. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past clinical and corporate updates have produced mixed price reactions, with several positive clinical readouts followed by negative or contrary moves.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.
The stock options have an exercise price of
The stock options are subject to the terms and conditions of the Tenaya Therapeutics Inc. 2024 Inducement Equity Incentive Plan and related forms of agreements and were granted as an inducement material to each new employee’s acceptance of employment with Tenaya in accordance with NASDAQ Listing Rule 5635(c)(4).
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
Contact Michelle Corral VP, Corporate Communications and Investor Relations IR@tenayathera.com